Analysed EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ) News Sources
Hypertrophic Cardiomyopathy Market Set for Transformation Over the Next Decade with the Emergence of Targeted Cardiac Therapies Beyond Conventional Beta-blockers, Calcium Channel Blockers, and Antiarrhythmic Agents | DelveInsight
17-08-2026
yahoo.com
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
16-06-2026
yahoo.com
Edgewise Therapeutics Remains Compelling Cardiology Story Despite Atrial Fibrillation Concerns, RBC Says
17-06-2026
yahoo.com
Edgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial Data
25-06-2026
yahoo.com
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
01-07-2026
yahoo.com
Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
13-07-2026
yahoo.com
Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business
13-07-2026
yahoo.com
What is the current price of EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ)?
The current price of EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ) is $44.21.
EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ) absolute price change since previous trading day?
The absolute price change of EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ) since the previous trading day is $-0.51.
EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ) percentage price change since previous trading day?
The percentage price change of EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ) since the previous trading day is -1.1404%.
What is the most recent average sentiment score for EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ)?
The most recent average sentiment score for EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ) is 86 out of 100.
What is the most recent average sentiment for EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ)?
The most recent sentiment for EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ) is .
SEC-8K** Filing Available For EDGEWISE THERAPEUTICS INC (EWTX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.